MLTX

MoonLake Immunotherapeutics Class A · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website moonlaketx.com
Employees(FY) 20
ISIN KY61559X1045

Performance

-3.99%

+1.8%

+1.59%

+25.33%

-17.5%

YTD

+16.76%

Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

Advanced Technical Analysis

Technical Analysis of MLTX 2024-11-20

The Moving Average Score of 70 indicates a bullish sentiment, while the Oscillators Score of 43 suggests a neutral stance, and the Technical Score of 56 reinforces a slightly positive outlook. Overall, the combined scores reflect a mixed sentiment, leaning towards bullish, but with caution due to the neutral oscillator reading.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MLTX

Stock Rank

Recent News & Updates

2024-11-13 08:00
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis(GlobeNewswire)
2024-11-12 19:00
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis(Globenewswire)
2024-11-07 09:30
MoonLake Immunotherapeutics' Q3 Net Loss Widens(MT Newswires)
2024-11-07 07:00
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update(GlobeNewswire)
2024-11-06 18:00
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-10-09 06:44
Daily – Vickers Top Buyers & Sellers for 10/09/2024(Argus Research)
2024-10-08 21:11
Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics(GuruFocus.com)
2024-10-08 16:07
Moonlake Immunotherapeutics Insider Sold Shares Worth $9,186,120, According to a Recent SEC Filing(MT Newswires)
2024-09-24 23:55
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?(Insider Monkey)
2024-09-23 02:44
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock(Insider Monkey)
2024-09-09 07:00
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11(GlobeNewswire)
2024-09-08 19:00
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11(Globenewswire)
2024-08-27 20:21
MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months(Insider Monkey)
2024-08-26 14:40
MoonLake Immunotherapeutics Shares Fall After Wolfe Research Downgrade(MT Newswires)
2024-08-26 06:05
Wolfe Research Downgrades MoonLake Immunotherapeutics to Peer Perform From Outperform(MT Newswires)
2024-08-22 12:25
We're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To Grow(Simply Wall St.)
2024-08-07 10:38
MoonLake Immunotherapeutics Shares Slightly Up Despite Wider Q2 Loss(MT Newswires)
2024-08-07 08:00
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11(GlobeNewswire)
2024-08-06 20:00
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11(Globenewswire)
2024-06-25 07:43
Oppenheimer Initiates MoonLake Immunotherapeutics at Outperform With $104 Price Target(MT Newswires)
2024-06-10 08:00
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis(GlobeNewswire)
2024-06-09 20:00
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis(Globenewswire)
2024-05-16 08:00
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa(GlobeNewswire)
2024-05-15 20:00
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa(Globenewswire)
2024-05-07 21:02
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes(GuruFocus.com)
2024-05-07 10:15
MoonLake Immunotherapeutics Q1 Net Loss Widens(MT Newswires)
2024-05-07 08:00
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update(GlobeNewswire)
2024-05-07 01:53
MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024(Investorplace)
2024-05-06 20:00
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-04-10 07:00
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions(Business Wire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.